Roche’s Genentech subsidiary filed a legal challenge in July against Biogen, seeking to block the entry of its Tofidence into the market and alleging infringement of various patents covering ...

During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global ...

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

GUANGZHOU, China, April 14, 2025 /PRNewswire/ -- Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...